STAND clinical trial results published

March 25, 2021 – Results of TB Alliance’s Phase 3 clinical trial, known as STAND, have been published in the International Journal of Tuberculosis and Lung Disease.

The STAND trial tested the potential of the novel three-drug regimen, PaMZ, to shorten and simplify treatment in both drug-sensitive tuberculosis (TB) and multidrug-resistant TB patients. The STAND trial was paused in September of 2015 and did not resume. A total of 284 patients were enrolled in the trial, which was conducted at 26 sites across 8 countries. Participants who completed treatment received six months of follow up, as well as additional monitoring for two years, as per the study design.

Access the full results at the International Journal of Tuberculosis and Lung Disease

Source: TB Alliance

To subscribe to the Weekly Newsletter of new posts, enter your email here:

By TB Alliance

Published: March 25, 2021, 9:58 p.m.

Last updated: April 3, 2021, 9 p.m.

Print Share